Original articleCFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and Zinc in Patients with Age-related Macular Degeneration
Section snippets
Methods
Study procedures of the AREDS have been reported.1 The AREDS dataset was provided by the database of genotypes and phenotypes under an investigator agreement. Patients had been characterized at AREDS enrollment, with retinal images classified by a central reading center.1
The AREDS participants varied at enrollment, ranging from those with normal eyes to those with advanced AMD. Disease was classified by the AREDS investigators based on the category of AMD in the patient's worse eye: AREDS
Patients
Of patients enrolled in the AREDS (n = 4757), white persons with AREDS category 3 disease in at least 1 eye at the time of enrollment (n = 2258) were selected for study. DNA was available from a subset of these (n = 995) from the Coriell Institute repository, collected under general research use or eye diseases only consent conditions. These samples constituted the sample set for our analysis.
To ensure that this sample set (n = 995) was representative of all white patients in AREDS with
Discussion
The AREDS demonstrated a beneficial effect of the AREDS formulation on progression to advanced AMD (adjusted odds ratio, 0.68; 99% confidence interval, 0.49–0.93).1 Although the average duration of treatment was 6.3 years, the beneficial effect of nutritional supplementation was sustained for at least a decade, suggesting value in life-long therapy.16
We present evidence, based on a large genetic dataset of patients with AREDS category 3 disease in 1 eye and AREDS category 1 through 4 disease in
References (27)
- et al.
Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease
J Mol Biol
(2008) - et al.
Complement factor H-ligand interactions: self-association, multivalency and dissociation constants
Immunobiology
(2012) - et al.
Zinc binding to the Tyr402 and His402 allotypes of complement factor H: possible implications for age-related macular degeneration
J Mol Biol
(2011) - et al.
Effect of dietary lutein and zeaxanthin on plasma carotenoids and their transport in lipoproteins in age-related macular degeneration
Am J Clin Nutr
(2007) - et al.
CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration
Ophthalmology
(2008) - et al.
Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations
J Biol Chem
(2010) - et al.
Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: a potential implication of zinc as an atheroprotective agent
Am J Clin Nutr
(2010) - et al.
The role of oxidative stress in the pathogenesis of age-related macular degeneration
Surv Ophthalmol
(2000) - et al.
Mitochondria: more than just a powerhouse
Curr Biol
(2006) A randomized, placebo-controlled, clinical trial of highdose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8
Arch Ophthalmol
(2001)
Inflammatory disease processes and interactions with nutrition
Br J Nutr
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA
Nat Genet
Hepatic lipase: a marker for cardiovascular disease risk and response to therapy
Curr Opin Lipidol
Cited by (98)
Age-Related Macular Degeneration
2021, Age-Related Macular DegenerationGene Therapy Intervention in Neovascular Eye Disease: A Recent Update
2020, Molecular TherapyReply
2020, OphthalmologyPredictive genetics for AMD: Hype and hopes for genetics-based strategies for treatment and prevention
2020, Experimental Eye ResearchCitation Excerpt :This observation still requires replication, but its importance should not be overlooked. Investigators have sought to know what patient genetic profile corresponds with treatment success using nutritional supplement interventions (Awh et al., 2013; Chew et al., 2015; Merle et al., 2015; Rojas-Fernandez and Tyber, 2017), anti-VEGF therapies for exudative AMD (Esteban et al., 2019; Fauser and Lambrou, 2015; Medina et al., 2019; Orlin et al., 2012; Park et al., 2014, 2017b; Riaz et al., 2016; Shah et al., 2016), complement suppressive therapies such as lampalizumab (Yaspan et al., 2017), photodynamic therapy (Parmeggiani et al., 2019) or strategies to modify lipid and retinoid metabolism(Fan et al., 2017; Wang et al., 2015). Our current treatment options for AMD are limited.
Clinical and immunological effects and biomarkers of zinc deficiency
2020, Essential and Toxic Trace Elements and Vitamins in Human Health
Financial Disclosure(s): The author(s) have made the following disclosure(s):
Carl C. Awh - Consultant, Scientific Advisory Board, Equity owner, Patents - ArcticDx
Steven Hawken - Consultant - ArcticDx
Brent Zanke - Employee, Equity owner, Patents - ArcticDx
Ivana K. Kim - Consultant, Scientific Advisory Board - ArcticDx
Supported by funding from ArcticDx, Inc., Toronto, Canada.